| Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response S Bhatia, D Diedrich, B Frieg, H Ahlert, S Stein, B Bopp, F Lang, T Zang, ... Blood, The Journal of the American Society of Hematology 132 (3), 307-320, 2018 | 69 | 2018 |
| Establishment and application of a novel patient-derived KIAA1549: BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing F Selt, J Hohloch, T Hielscher, F Sahm, D Capper, A Korshunov, D Usta, ... Oncotarget 8 (7), 11460, 2017 | 55 | 2017 |
| Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines K Stenzel, A Hamacher, FK Hansen, CGW Gertzen, J Senger, ... Journal of medicinal chemistry 60 (13), 5334-5348, 2017 | 46 | 2017 |
| CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells D Maciaczyk, D Picard, L Zhao, K Koch, D Herrera-Rios, G Li, ... British journal of cancer 117 (1), 102-112, 2017 | 41 | 2017 |
| The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma U Ahmadov, D Picard, J Bartl, M Silginer, M Trajkovic-Arsic, N Qin, ... Cell death & disease 12 (10), 885, 2021 | 34 | 2021 |
| Design, synthesis and 3D-QSAR studies of novel 1, 4-dihydropyridines as TGFβ/Smad inhibitors D Längle, V Marquardt, E Heider, B Vigante, G Duburs, I Luntena, ... European Journal of Medicinal Chemistry 95, 249-266, 2015 | 28 | 2015 |
| N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma B Tjaden, K Baum, V Marquardt, M Simon, M Trajkovic-Arsic, T Kouril, ... Scientific Reports 10 (1), 7157, 2020 | 26 | 2020 |
| The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors J Bartl, M Zanini, F Bernardi, A Forget, L Blümel, J Talbot, D Picard, N Qin, ... Nature communications 13 (1), 4061, 2022 | 17 | 2022 |
| A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade … D Usta, R Sigaud, JL Buhl, F Selt, V Marquardt, D Pauck, J Jansen, ... Molecular cancer therapeutics 19 (8), 1736-1750, 2020 | 17 | 2020 |
| Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to … V Marquardt, J Theruvath, D Pauck, D Picard, N Qin, L Blümel, M Maue, ... Journal for ImmunoTherapy of Cancer 11 (1), 2023 | 15 | 2023 |
| Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity N Reßing, V Marquardt, CGW Gertzen, A Schöler, A Schramm, T Kurz, ... MedChemComm 10 (7), 1109-1115, 2019 | 15 | 2019 |
| Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses AC Nickel, D Picard, N Qin, M Wolter, K Kaulich, M Hewera, D Pauck, ... Biomedicine & Pharmacotherapy 144, 112278, 2021 | 8 | 2021 |
| Establishment and application of a novel patientderived KIAA1549: BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget 8: 11460–11479 F Selt, J Hohloch, T Hielscher, F Sahm, D Capper, A Korshunov, D Usta, ... | 7 | 2017 |
| IMMU-19. HDAC inhibitors sensitize MYC-AMPLIFIED medulloblastoma to immunotherapy by activating the NF-kB pathways V Marquardt, J Theruvath, D Pauck, D Picard, G Reifenberger, ... Neuro-Oncology 22 (Suppl 3), iii363, 2020 | 2 | 2020 |
| IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM … V Marquardt, J Theruvath, N Qin, D Picard, R Vibhakar, S Venkararaman, ... Neuro-Oncology 25 (Suppl 1), i50, 2023 | | 2023 |
| IMMU-38. MYC DRIVEN IMMUNE SUPPRESSION IN GROUP 3 MEDULLOBLASTOMA S Mitra, D Picard, N Qin, A Cole, JC Cruz, V Marquardt, S Venkataraman, ... Neuro-Oncology 24 (Supplement_7), vii139-vii139, 2022 | | 2022 |
| HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-KB PATHWAYS V Marquardt, J Theruvath, D Pauck, D Picard, G Reifenberger, ... NEURO-ONCOLOGY 22, 364-364, 2020 | | 2020 |
| LGG-17. SYNERGISTIC ACTIVITY OF MAPK INHIBITOR CLASSES REVEALED BY A NOVEL CELL-BASED MAPK ACTIVITY PEDIATRIC LOW-GRADE GLIOMA ASSAY D Usta, R Sigaud, JL Buhl, F Selt, V Marquardt, D Pauck, S Pusch, J Ecker, ... Neuro-Oncology 22 (Supplement_3), iii369-iii369, 2020 | | 2020 |
| EPEN-33. PHARMACOGENOMICS REVEALS SYNERGISTIC INHIBITION OF ERBB2 AND PI3K SIGNALING AS A THERAPEUTIC STRATEGY FOR EPENDYMOMA D Pauck, E Paisana, R Cascão, S Sarikaya-Seiwert, V Marquardt, ... Neuro-Oncology 22 (Supplement_3), iii314-iii314, 2020 | | 2020 |
| MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA K Taban, D Pauck, M Maue, V Marquardt, H Yu, O Ayrault, D Picard, ... Neuro-Oncology 22 (Supplement_3), iii406-iii406, 2020 | | 2020 |
